Home Financial responsibility Senior Pharmaceutical Industry Executive Dr Elisabeth Svanberg appointed Chairman of the Board of Pharnext

Senior Pharmaceutical Industry Executive Dr Elisabeth Svanberg appointed Chairman of the Board of Pharnext


PARIS, FRANCE / ACCESSWIRE / December 23, 2021 / Pharnext SA (FR0011191287 – ALPHA) (the “Company”), an advanced clinical biopharmaceutical company pioneering new approaches to develop innovative drug combinations based on large genomic data and artificial intelligence using its PLEOTHERAPY platform (TM), announces today the appointment of Dr Elisabeth Svanberg MD, PhD succeeds Michel de Rosen as Chairman of the Board of Directors effective January 1, 2022. Michel de Rosen has been Chairman of the Board of Directors since June 2016 and will continue to serve as a non-executive Director.

Dr Svanberg has extensive experience in the development of new treatments in all therapeutic areas. She holds an MD and PhD from the University of Gothenburg and is a general surgeon and a certified associate professor of surgery. She is an experienced non-executive director who sits on the boards of Galapagos NV, Egetis Pharmaceuticals, Amolyt and Swedish Orphan Biovitrum (SOBI).

Dr Svanberg joined Serono in 2000, first in the field of metabolism, then held positions of increasing responsibility before joining Bristol Myers Squibb (BMS) in 2007. At BMS, she was responsible for the development of dapagliflozin (Forxiga / Farxiga), a first-in-class drug now registered and launched worldwide to treat type 2 diabetes, and then served as Vice President and Head of Intercontinental Medical Service responsible for Canada, Latin America , Middle East & Africa, Asia Pacific, and Australia / New Zealand. In 2014, Dr Svanberg joined Janssen Pharmaceuticals (a Johnson & Johnson company) as Vice President, Head of the Established Products group, managing a portfolio of 90 products used by approximately 150 million patients worldwide. Since 2016, Dr Svanberg has been an entrepreneur in the field of urogenital disorders.

Dr. Svanberg’s experience will greatly benefit Pharnext as the Company advances its pivotal Phase III clinical study of PXT3003, the PREMIER trial, its lead drug candidate designed to treat Charcot-Marie-Tooth disease. type 1A (CMT1A). CMT1A is a rare progressive inherited neurological disorder that affects peripheral nerves and currently has no approved treatment.

Upon her appointment as Chairman of the Board, Dr Elisabeth Svanberg said: “I am delighted to take on the role of Chairman at this important time for Pharnext and to work alongside my fellow Board members. administration and our leadership team to support the Company as it advances the pivotal study of PXT3003 in CMT1A. I would like to thank Michel and the Board of Directors of Pharnext for the confidence they have placed in me. Michel led the Company at this pivotal moment, and I look forward to continuing to build on Michel’s foundations. I am delighted that Michel is staying to continue his support for the transition. “

Michel de Rosen, outgoing Chairman of the Board of Directors of Pharnext, said: “After having chaired the Board of Directors of Pharnext for more than five years, I believe that the time has come for a new person to take on this role. . Elisabeth Svanberg is remarkably qualified for this mission. His expertise in drug development, his experience in senior management and on biotechnology boards, his international background, his leadership qualities, his rigor and his integrity will be invaluable assets for the Pharnext Board of Directors. in the evolution of the company. Pharnext and in particular in its drug candidate CMT1A. “

About Pharnext

Pharnext is an advanced clinical biopharmaceutical company developing new therapies for orphan and common neurodegenerative diseases that currently lack curative and / or disease-modifying treatments. Pharnext has two flagship products in clinical development. PXT3003 has completed an international phase III trial with positive results for the treatment of Charcot-Marie-Tooth disease type 1A (“CMT1A”) and has orphan drug status in Europe and the United States. A phase III international pivotal study of PXT3003 in CMT1A, the PREMIER trial, is currently underway. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY (TM). Pharnext identifies and develops synergistic drug combinations called PLEODRUG (TM). More information can be found at www.pharnext.com .

Pharnext is listed on the Euronext Venture Exchange in Paris (ISIN code: FR0011191287).


This press release contains certain forward-looking statements regarding Pharnext and its business, including with respect to the timing and outlook for clinical trials and regulatory submissions of the Company’s product candidates as well as a possible financing transaction, use of the product of these and the cash track. These forward-looking statements are based on assumptions that Pharnext considers to be reasonable. However, there can be no assurance that the estimates contained in these forward-looking statements will be verified, which estimates are subject to numerous risks, including the risks set out in the Pharnext URD approved by the AMF on November 9, 2020 under number N ° R 20 -029 as well as in its periodic annual management reports and press releases (copies of which are available on www.pharnext.com) and to changes in economic conditions, financial markets and the markets in which Pharnext operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Pharnext or currently considered to be immaterial by Pharnext. The occurrence of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Pharnext to differ materially from these forward-looking statements. Pharnext disclaims any intention or obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe to Pharnext shares in any country whatsoever, including the United States. United. The securities of the Company may not be offered or sold in the United States without registration or exemption from registration; any public offering of securities to be made in the United States will be made by means of a prospectus which may be obtained from the issuer and which will contain detailed information on the Company and management, as well as financial statements.


Dr David Horn Salomon
Chief executive officer
[email protected]
+33 (0) 1 41 09 22 30

Media Relations (International)

Strategic Communication Consilium
Mary-Jane Elliott
Sukaina virji
Alexandra harrison
[email protected]

Financial Communication (Europe)

Ghislaine Gasparetto
[email protected]
+33 (0) 6 21 10 49 24

Press relations (France)

Ulysses Communication
Bruno Arab
[email protected]
+33 (0) 6 87 88 47 26
+33 (0) 1 81 70 96 30

THE SOURCE: Pharnext

See the source version on accesswire.com: